OncBioMune Pharmaceuticals

OncBioMune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer immunotherapy products. The company's headquarters are located in Baton Rouge, Louisiana. OncBioMune Pharmaceuticals operates within the healthcare, pharmaceuticals, and biotechnology industries. The company's primary focus is on the development of novel cancer immunotherapy products. OncBioMune's lead product is ProscaVax™, a therapeutic vaccine currently undergoing Phase 2 clinical trials for prostate cancer. This vaccine utilizes proprietary vaccine technology, which has been proven safe in over 300 patients. OncBioMune Pharmaceuticals' target clients are within the healthcare, pharmaceutical, and biotechnology sectors. The company is committed to providing solutions for cancer treatment and demonstrates transparency with both the industry and its shareholders. OncBioMune Pharmaceuticals' competitive advantages include its proprietary vaccine technology, which has a proven safety record, and its lead product, ProscaVax™, which is in Phase 2 clinical trials for prostate cancer. The company's leadership team includes Dr. Brian Barnett, M.D., as Chief Executive Officer; Andrew Kucharchuk as Chief Financial Officer, President, and Director; and Dr. Jonathan Head, Ph.D., as Chairman of the Board and Chief Scientific Officer. The Scientific Advisory Board includes Dr. J. Jacques Carter. Daniel Hoverman also serves as a Director. OncBioMune Pharmaceuticals is committed to finding answers for cancer. The company's values include a commitment to transparency and dedication to both the industry and its shareholders. The company can be contacted via phone at 1-225-227-2384 or 1-225-227-2957, email at [email protected], or by visiting their office at 11441 Industriplex Blvd. Suite 190 Baton Rouge, LA 70809.